ChinaAMC CSI Biotechnology Theme ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

159892

ARKG

512290

159316

516500

159102

516930

588250

588130

512010

159849

159837

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

prnewswire

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

iShares Biotechnology ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

VG Health

iShares US Pharma

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Biotech

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Bosera Hang Seng Health Care ETF(QDII)

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

00945

516820

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

MANULIFE-S

Manulife Financial

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP CSI Medical Service ETF

Direxion S&P Biotech Bear 3X

Manulife Singapore to offer multi-cancer blood test starting May

Analyst David Martin PhD of Bloom Burton has reiterated a Buy rating on Microbix Biosystems with a price target of C$0.40. He attributes the recent revenue shortfall to a temporary slowdown in Chinese antigen orders, not structural issues. Demand from non-Chinese customers is increasing, and Microbix has diversified its revenue base, reducing future volatility. This positioning, along with the potential for sales normalization, presents an attractive risk-reward profile.

Tip Ranks

MBX Biosciences

Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand

02359

159570

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

WUXI APPTEC

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP CSI Pharmaceuticals ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

WuXi AppTec

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

01801

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

Fingerprint Cards AB reported a mixed Q1 earnings call, highlighting a 4% revenue growth and a 62.3% gross margin, despite challenges like negative EBITDA and tight cash. The company is banking on a merger with Precise Biometrics to address its subscale cost base, aiming for significant annual cost synergies. AllKey platform is emerging as a key growth driver, representing 75% of the Q1 pipeline. However, the company faces liquidity pressures and must successfully execute the merger to achieve sustainable profitability.

Fingerprint Cards AB Bets on Merger-Led Turnaround

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

Unusual Whales

BlackRock, Inc.

iShares Global Healthcare

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

000688

科创综指

588170

The STAR Market has risen 78.98% in the past year, gathering 609 hard technology companies, with a total market value exceeding 13 trillion yuan. In 2025, revenue is expected to be nearly 1.6 trillion yuan, with a net profit exceeding 58.6 billion yuan. In the first quarter of 2026, revenue is projected to be 385.3 billion yuan, with a net profit attributable to the parent company of 23.4 billion yuan, a year-on-year increase of nearly 200%. The "1+6" system of the STAR Market promotes the development of technology companies, focusing on fields such as artificial intelligence and commercial aerospace, showcasing the innovative vitality and development potential of hard technology enterprises

同壁财经

STAR 50

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

E Fund China Science and Technology Innovation Board 50 Component ETF

Huatai-PB SSE Science and Technology Innovation Board Composite ETF

ChinaAMC SSE Science and Technology Innovation Board 50 ETF

ChinaAMC SSE Science and Technology Innovation Board Composite ETF

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

Guotai CES Semiconductor Chip Industry ETF

Huatai-PB SSE Science and Technology Innovation Board 50 ETF

Guotai CSI Semiconductor Material Equipment Theme ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

TF SECURITIES

CCB Principal SSE Science and Technology Innovation Board Composite ETF

The STAR Market's performance has exploded, with net profit increasing by nearly 200% in the first quarter, gathering integrated circuits, biomedicine, and high-end equipment. The STAR Composite Index has risen by 78.98% in nearly one year

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

300347

03347

Citi reported that TIGERMEDshares fell by 5.26% due to compliance issues involving its co-founders' failure to disclose equity changes. Despite this, Citi believes the company's fundamentals remain strong and views the share price decline as a buying opportunity. The broker assigned a target price of RMB67 for TIGERMED CONSULTINGand maintained a Buy rating.

AASTOCKS News

Tigermed

TIGERMED

Citi: TIGERMED CONSULTING Fundamentals Unaffected; Share Price Weakness Seen as Entry Pt

ChinaAMC CSI Biotechnology Theme ETF(516500.SH)